Modiwart (Imiquimod)

Imiquimod, the active ingredient in Modiwart, is a immune response modifier presented as a unknown/unknown for topical (cutaneous) use. It treats actinic keratosis, superficial basal cell carcinoma and external genital warts in appropriate patients.

GNH USA supplies Modiwart as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Imiquimod is indicated for skin conditions that benefit from a localized immune response.

Actinic keratosis: promotes clearance of precancerous lesions on sun‑damaged skin. Superficial basal cell carcinoma: induces tumor regression in early‑stage skin cancer. External genital warts: stimulates antiviral immunity to eliminate HPV‑related lesions.

Imiquimod may cause a range of skin reactions, from mild irritation to severe inflammation.

Common Side Effects: - Erythema: redness at the application site. - Pruritus: itching or mild discomfort. - Burning sensation: transient heat feeling. - Pain: localized soreness. - Crusting or scaling: formation of dry patches. - Swelling: mild edema around treated area.

Serious or Rare Side Effects: - Severe contact dermatitis: extensive rash with blistering. - Exfoliative dermatitis: widespread skin shedding. - Systemic flu‑like symptoms: fever, chills, malaise. - Lymphadenopathy: swollen lymph nodes near the treated region. - Hypersensitivity reaction: urticaria or angioedema. - Secondary infection: bacterial overgrowth at irritated sites.

When prescribing Modiwart, clinicians should consider several safety measures.

Assess skin condition: ensure lesions are appropriate for topical immunotherapy. Avoid application on broken skin: do not apply to open wounds or ulcerated areas. Monitor for excessive inflammation: discontinue if severe redness or ulceration occurs. Avoid concurrent use with other topical irritants: limit combination with harsh chemicals. Pregnancy and lactation: consult a healthcare professional before use. Store at room temperature: keep in the original container, protect from moisture and light.

Imiquimod can interact with other agents that affect skin immunity or irritation.

Major Interactions (Avoid): - Concurrent use with other immune‑modulating topicals: may increase local irritation. - Systemic immunosuppressants (e.g., corticosteroids, biologics): may reduce therapeutic efficacy.

Moderate Interactions (Monitor Closely): - Topical corticosteroids: may diminish Imiquimod’s immune response. - Phototherapy or UV exposure: may heighten skin sensitivity. - Live vaccines: theoretical risk of altered immune response. - Antiviral creams containing acyclovir: may interfere with antiviral activity. - Herbal skin preparations: monitor for additive irritation.